Hospital-exemption cell therapies at scale, backed by a shared registry
European law already lets hospitals make advanced therapies for their own patients. Pair that with a shared outcomes registry so academic CAR-Ts and similar treatments can prove themselves without a commercial licence.
The EU hospital exemption (and analogous national point-of-care manufacturing provisions in the UK, Spain, Japan and elsewhere) permits non-routine manufacture of advanced therapy medicinal products for individual patients under national oversight. It is used unevenly and generates little comparable evidence. The proposal is a harmonised framework: common quality standards, a mandatory prospective registry with standard outcome and toxicity capture, and a defined pathway by which registry evidence supports wider use or a conditional marketing authorisation. This lets academic products reach patients years earlier and creates a real-world evidence base for regulators.
- The valley of death between lab and product · Most academic discoveries die before anyone tests them in people because nobody funds the middle step.
- Manufacturing cost and time for living and radioactive medicines · Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.
- Regulatory divergence between regions · Regulatory divergence means a drug approved in one country can take years to reach another, or never arrive.
Pages like this
not linked directly; found by shared links- IdeaShared modular GMP facilities for academic personalised vaccines and cell products
Shares Hospital-based CAR-T manufacturing at cost through a public network, Regional translational institutes with academic GMP suites and IND teams, TIL therapy, The valley of death between lab and product.
- IdeaPublic cell-therapy foundries at cancer centres for academics and start-ups
Shares TIL therapy, TCR-T cell therapy, The valley of death between lab and product, Manufacturing cost and time for living and radioactive medicines.
- IdeaA global first-in-human network for academic cancer trials with single ethics review
Shares A public indemnity pool so universities can sponsor first-in-human cancer trials, Regional translational institutes with academic GMP suites and IND teams, The valley of death between lab and product, Regulatory divergence between regions.
- IdeaA national non-profit contract research organisation for academic oncology trials
Shares A public indemnity pool so universities can sponsor first-in-human cancer trials, Regional translational institutes with academic GMP suites and IND teams, The valley of death between lab and product.
- IdeaAn open interoperability standard for closed automated cell-processing machines
Shares TIL therapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaDigital batch records and AI process control to halve cell therapy batch failures
Shares TIL therapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaMutual recognition of GMP inspections for cell, gene and radiopharmaceutical plants
Shares Regulatory divergence between regions, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- IdeaComparability by design: a digital twin and sentinel panel for cell process changes
Shares Regulatory divergence between regions, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.